Ariad Pharmaceuticals (ARIA) 5.87 $ARIA
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
Business Wire - Fri Oct 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig(R) (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events.
ARIA: 5.87 (-0.10)
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind
PR Newswire - Tue Oct 21, 7:55AM CDT
Insiderslab.com, a U.S. market research community with a special focus on updating investors with insider trading news, revealed the latest insider trading alerts for U.S. stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Micron (NASDAQ:MU), CSX (NYSE:CSX), Ariad Pharmaceuticals (NASDAQ:ARIA), International Business Machines (NYSE:IBM), SinoCoking Coal and Coke Chemical (NASDAQ:SCOK), and MannKind (NASDAQ:MNKD).
MU: 32.28 (-0.33), SCOK: 2.90 (-0.07), IBM: 163.46 (-0.14), ARIA: 5.87 (-0.10), MNKD: 6.07 (-0.11), CSX: 35.40 (+0.11)
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power
PR Newswire - Mon Oct 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Halliburton (NYSE:HAL), Ariad Pharmaceuticals (NASDAQ:ARIA), KeyCorp (NYSE:KEY), GoPro (NASDAQ:GPRO), MannKind (NASDAQ:MNKD), and Plug Power (NASDAQ
LUG).
GPRO: 67.89 (-1.41), PLUG: 4.44 (+0.02), HAL: 54.42 (+1.16), KEY: 13.11 (+0.11), ARIA: 5.87 (-0.10), MNKD: 6.07 (-0.11)
16.9% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 15, 9:32AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 16.90% as of today's recent price of $5.04.
ARIA: 5.87 (-0.10)
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
PR Newswire - Wed Oct 15, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation (NASDAQ: GERN), and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 14, 2014, the NASDAQ Composite ended at 4,227.17, up 0.32%, the Dow Jones Industrial Average edged 0.04% lower, to finish the day at 16,315.19, and the S&P 500 closed at 1,877.70, up 0.16%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, with the index also declining 1.35% in the previous three months. Register for your complimentary reports on these five stocks at:
GERN: 2.26 (-0.08), NVAX: 5.41 (-0.07), CLDX: 16.85 (-0.21), GALE: 2.14 (+0.08), ARIA: 5.87 (-0.10)
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results
Business Wire - Wed Oct 15, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
ARIA: 5.87 (-0.10)
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:05PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
AMPE: 3.81 (-0.14), BMY: 54.16 (-0.04), ARIA: 5.87 (-0.10), NVS: 91.31 (-1.04)
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:55PM CDT
Amgen (AMGN) provided an update on its cancer candidate, blinatumomab.
MDVN: 99.55 (-1.63), LGND: 53.33 (+1.44), AMGN: 158.88 (+1.69), ARIA: 5.87 (-0.10)
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Business Wire - Fri Oct 10, 6:44AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig(R) (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications.
ARIA: 5.87 (-0.10)
Ariad Pharmaceuticals Shares Down 13.4% Since SmarTrend's Sell Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 08, 9:26AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 13.44% as of today's recent price of $5.25.
ARIA: 5.87 (-0.10)
ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 4:49PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the FDA has granted Breakthrough Therapy designation to its lung cancer candiadate, AP26113 for the treatment of ALK+ non-small cell lung cancer (NSCLC).
PFE: 29.49 (+0.40), ARIA: 5.87 (-0.10), HPTX: 23.13 (-0.50)
ARIAD and Bellicum Announce Revised License Agreement for ARIAD's Cell-Signaling Technology
Business Wire - Mon Oct 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc. today announced a restructuring of their license agreement for ARIAD's cell-signaling technology. ARIAD will receive $50 million in exchange for a fully paid up license to this technology and return of its equity stake in closely held Bellicum. The scope of the license and the field of use were also expanded as part of the amendment.
ARIA: 5.87 (-0.10)
Watch for Ariad Pharmaceuticals to Potentially Pullback After Gaining 10.80% Yesterday
Comtex SmarTrend(R) - Thu Oct 02, 4:43PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.62 to a high of $5.96. Yesterday, the shares gained 10.8%, which took the trading range above the 3-day high of $5.90 on volume of 19.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 5.87 (-0.10)
Rite Aid and Ariad are big market movers
AP - Thu Oct 02, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
HK: 3.19 (+0.13), DAL: 39.58 (-0.26), GRMN: 53.96 (-3.24), STZ: 89.17 (-0.68), MGM: 22.89 (-0.02), STZ.B: 89.08 (-0.41), RAD: 5.25 (+0.19), WPRT: 6.08 (-0.20), ANGI: 6.57 (-0.17), WPT.TO: 6.79 (-0.23), LAKE: 11.58 (-0.66), ARIA: 5.87 (-0.10), GIS: 50.90 (-0.48), CREE: 31.84 (-0.31)
Why Ariad Pharmaceuticals, Inc. Stock Catapulted Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 02, 12:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ariad Pharmaceuticals , a...
ARIA: 5.87 (-0.10)
Free Fall Continues For Freddie Mac, Fannie Mae
at The Street - Thu Oct 02, 11:44AM CDT
Today's top-performing billionaire stock picks midday are Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Neonode, Inc (NASDAQ:NEON) and AutoNation, Inc. (NYSE:AN). The losers are Freddie Mac / Federal H...
NEON: 2.01 (-0.11), ARIA: 5.87 (-0.10), AN: 55.76 (+0.18)
Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today
at The Street - Thu Oct 02, 10:23AM CDT
Ariad Pharmaceuticals (ARIA) shares are up after its lung cancer treatment was given a 'breakthrough therapy' designation by the FDA.
PFE: 29.49 (+0.40), ARIA: 5.87 (-0.10)
ARIAD's AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib
Business Wire - Thu Oct 02, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib. This designation is based on results from the ongoing Phase 1/2 trial that show sustained anti-tumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases.
ARIA: 5.87 (-0.10)
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
Business Wire - Mon Sep 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data of AP26113, including increasing depth and durability of response in ALK+ NSCLC patients, as well as additional safety data.
ARIA: 5.87 (-0.10)
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe
Business Wire - Fri Oct 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig(R) (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events.
ARIA: 5.87 (-0.10)
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind
PR Newswire - Tue Oct 21, 7:55AM CDT
Insiderslab.com, a U.S. market research community with a special focus on updating investors with insider trading news, revealed the latest insider trading alerts for U.S. stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Micron (NASDAQ:MU), CSX (NYSE:CSX), Ariad Pharmaceuticals (NASDAQ:ARIA), International Business Machines (NYSE:IBM), SinoCoking Coal and Coke Chemical (NASDAQ:SCOK), and MannKind (NASDAQ:MNKD).
MU: 32.28 (-0.33), SCOK: 2.90 (-0.07), IBM: 163.46 (-0.14), ARIA: 5.87 (-0.10), MNKD: 6.07 (-0.11), CSX: 35.40 (+0.11)
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power
PR Newswire - Mon Oct 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Halliburton (NYSE:HAL), Ariad Pharmaceuticals (NASDAQ:ARIA), KeyCorp (NYSE:KEY), GoPro (NASDAQ:GPRO), MannKind (NASDAQ:MNKD), and Plug Power (NASDAQ
LUG). GPRO: 67.89 (-1.41), PLUG: 4.44 (+0.02), HAL: 54.42 (+1.16), KEY: 13.11 (+0.11), ARIA: 5.87 (-0.10), MNKD: 6.07 (-0.11)
16.9% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 15, 9:32AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 16.90% as of today's recent price of $5.04.
ARIA: 5.87 (-0.10)
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
PR Newswire - Wed Oct 15, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation (NASDAQ: GERN), and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 14, 2014, the NASDAQ Composite ended at 4,227.17, up 0.32%, the Dow Jones Industrial Average edged 0.04% lower, to finish the day at 16,315.19, and the S&P 500 closed at 1,877.70, up 0.16%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, with the index also declining 1.35% in the previous three months. Register for your complimentary reports on these five stocks at:
GERN: 2.26 (-0.08), NVAX: 5.41 (-0.07), CLDX: 16.85 (-0.21), GALE: 2.14 (+0.08), ARIA: 5.87 (-0.10)
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results
Business Wire - Wed Oct 15, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
ARIA: 5.87 (-0.10)
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:05PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
AMPE: 3.81 (-0.14), BMY: 54.16 (-0.04), ARIA: 5.87 (-0.10), NVS: 91.31 (-1.04)
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:55PM CDT
Amgen (AMGN) provided an update on its cancer candidate, blinatumomab.
MDVN: 99.55 (-1.63), LGND: 53.33 (+1.44), AMGN: 158.88 (+1.69), ARIA: 5.87 (-0.10)
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Business Wire - Fri Oct 10, 6:44AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig(R) (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications.
ARIA: 5.87 (-0.10)
Ariad Pharmaceuticals Shares Down 13.4% Since SmarTrend's Sell Call (ARIA)
Comtex SmarTrend(R) - Wed Oct 08, 9:26AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 3 months, Ariad Pharmaceuticals has returned 13.44% as of today's recent price of $5.25.
ARIA: 5.87 (-0.10)
ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 4:49PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the FDA has granted Breakthrough Therapy designation to its lung cancer candiadate, AP26113 for the treatment of ALK+ non-small cell lung cancer (NSCLC).
PFE: 29.49 (+0.40), ARIA: 5.87 (-0.10), HPTX: 23.13 (-0.50)
ARIAD and Bellicum Announce Revised License Agreement for ARIAD's Cell-Signaling Technology
Business Wire - Mon Oct 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc. today announced a restructuring of their license agreement for ARIAD's cell-signaling technology. ARIAD will receive $50 million in exchange for a fully paid up license to this technology and return of its equity stake in closely held Bellicum. The scope of the license and the field of use were also expanded as part of the amendment.
ARIA: 5.87 (-0.10)
Watch for Ariad Pharmaceuticals to Potentially Pullback After Gaining 10.80% Yesterday
Comtex SmarTrend(R) - Thu Oct 02, 4:43PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.62 to a high of $5.96. Yesterday, the shares gained 10.8%, which took the trading range above the 3-day high of $5.90 on volume of 19.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 5.87 (-0.10)
Rite Aid and Ariad are big market movers
AP - Thu Oct 02, 3:34PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
HK: 3.19 (+0.13), DAL: 39.58 (-0.26), GRMN: 53.96 (-3.24), STZ: 89.17 (-0.68), MGM: 22.89 (-0.02), STZ.B: 89.08 (-0.41), RAD: 5.25 (+0.19), WPRT: 6.08 (-0.20), ANGI: 6.57 (-0.17), WPT.TO: 6.79 (-0.23), LAKE: 11.58 (-0.66), ARIA: 5.87 (-0.10), GIS: 50.90 (-0.48), CREE: 31.84 (-0.31)
Why Ariad Pharmaceuticals, Inc. Stock Catapulted Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 02, 12:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ariad Pharmaceuticals , a...
ARIA: 5.87 (-0.10)
Free Fall Continues For Freddie Mac, Fannie Mae
at The Street - Thu Oct 02, 11:44AM CDT
Today's top-performing billionaire stock picks midday are Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Neonode, Inc (NASDAQ:NEON) and AutoNation, Inc. (NYSE:AN). The losers are Freddie Mac / Federal H...
NEON: 2.01 (-0.11), ARIA: 5.87 (-0.10), AN: 55.76 (+0.18)
Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today
at The Street - Thu Oct 02, 10:23AM CDT
Ariad Pharmaceuticals (ARIA) shares are up after its lung cancer treatment was given a 'breakthrough therapy' designation by the FDA.
PFE: 29.49 (+0.40), ARIA: 5.87 (-0.10)
ARIAD's AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib
Business Wire - Thu Oct 02, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib. This designation is based on results from the ongoing Phase 1/2 trial that show sustained anti-tumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases.
ARIA: 5.87 (-0.10)
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer
Business Wire - Mon Sep 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data of AP26113, including increasing depth and durability of response in ALK+ NSCLC patients, as well as additional safety data.
ARIA: 5.87 (-0.10)
